<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Dxterity Diagnostics Incorporated. The contract is for the development of a blood test to predict radiation toxicity in patients treated with radiation therapy. The contract has a total potential value of $1,396,540.45 and a period of performance from September 19, 2016 to August 19, 2021. The contract is a cost-plus-fixed-fee Definitive Contract.</p>
This is a Small Business Set-Aside contract awarded by the National Cancer Institute (NCI), a civilian agency, to DiaCarta L.L.C., a minority-owned, for-profit limited liability company. The $299,698.00 firm-fixed-price contract is for a Small Business Technology Transfer (STTR) Phase I research project to develop "Predictive Biomarkers of Adverse Reactions to Radiation Treatment" over a period from September 19, 2016 to June 18, 2017. The contract does not appear to be associated with...
<p>This is a $1,999,984.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Diacarta, Inc. The contract is for the TOPIC 345 - SBIR PHASE II: RADTOX - MEASURING RADIATION TOXICITY USING CIRCULATING DNA project, which aims to develop a method for measuring radiation toxicity using circulating DNA. The contract has a Firm Fixed Price pricing type and is set to be completed by March 15, 2023.</p>
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Radiopharmaceutical Imaging and Dosimetry, LLC, doing business as Radiopharmaceutical Imaging & Dosimetry LLC, a small business. The contract, valued at $299,275, is for a Small Business Innovation Research (SBIR) Phase I project to optimize targeted radionuclide therapy for metastatic liver cancer patients. This contract supports the NCI's broader...
This is a $1,994,911.00 firm fixed price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Earlydiagnostics Inc., doing business as Earlydx. The contract was awarded under the NCI SBIR Transition to Phase II Solicitation for fiscal year 2023 and has a total small business set-aside designation. Earlydx, a for-profit organization, will provide research and development services to support the development of a cloud-based...
<p>This is a $150,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Bioptix Diagnostics, Inc., a for-profit manufacturer. The contract is for Phase I of a Small Business Innovation Research (SBIR) project under Topic 281. The contract has a completion date of June 29, 2011. As an SBIR award, this contract was set aside for small businesses.</p>
This is a Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Tetraimaging LLC, a self-certified small disadvantaged business. The contract, valued at $1,999,930.00, is for the development of a multilayer strip ion chamber device to measure flash-RT beams under the SBIR (Small Business Innovation Research) Program Phase II. The period of performance is from September 16, 2024, to September 15, 2026, and the contract has a total small...
This contract was awarded by the National Institutes of Health (NIH), which is part of the U.S. Department of Health and Human Services (HHS). It is a Small Business Innovation Research (SBIR) Phase II contract awarded to Mira DX Inc., a Woman-Owned Small Business (WOSB). The contract has a potential value of $1,999,999.00 and is a Firm Fixed Price contract. The contract was awarded under Topic 338 of the SBIR program, which is focused on "Defining Normal Tissue and Tumor Biomarkers of...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
This is a $396,190 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (part of the National Institutes of Health) to Tetraimaging LLC, a small disadvantaged business, to develop ultra-fast dose rate (FLASH) radiation detectors and safety systems. The contract was awarded on September 16, 2022 and is set to complete by December 15, 2023. The original solicitation, PHS-2022-1, announced by the NIH and CDC, sought small business...
This is a small business set-aside contract awarded by the National Cancer Institute (NCI), a civilian agency, to Dxterity Diagnostics Incorporated. The contract is for the development of a blood test to predict radiation toxicity in patients undergoing radiation therapy, as part of the Small Business Innovation Research (SBIR) program. The definitive, firm-fixed price contract has a ceiling value of $280,005.00 and a performance period ending on March 31, 2015.